オンコロジーバイオシミラーの世界市場レポート 2025年

オンコロジーバイオシミラー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR16.8%で164億8,000万米ドルに成長します。予測期間の成長は、がん領域のバイオシミラーポートフォリオの拡大、患者中心の医療、ヘルスケアコストの抑制、標的治療、パイプラインの拡大に起因すると考えられます。予測期間の主な動向には、バイオベッター、がん領域のバイオシミラー併用、支持療法バイオシミラー、リアルワールドエビデンスなどがあります。

がん治療に利用される生物製剤の特許切れにより、新たなオンコロジーバイオシミラーの開発に拍車がかかっています。生物に由来する生物学的製剤の特許寿命には限りがあるため、生物学的製剤に類似するが同一ではない、同等の有効性を低コストで提供するバイオシミラーが出現する機会が生まれています。がん領域の生物製剤の特許は2023年までに20件近くが期限切れとなり、新たなオンコロジーバイオシミラーの生産を促しています。このような特許切れの増加により、バイオシミラーの需要が高まり、オンコロジーバイオシミラー市場の成長に拍車がかかると予想されます。

がん対策に向けた政府の取り組みは、オンコロジーバイオシミラー市場の成長を促進する構えです。こうした取り組みとは、特定の問題に対処したり特定の目的を達成したりするために、政府機関がさまざまなレベルで導入する行動や政策を指します。がん罹患率を低下させる努力は、オンコロジーバイオシミラーの開発と採用に資する環境を作り出します。例えば、2022年、バイデン大統領はCancer Moonshotの活性化を発表し、25年以内にがん死亡率を半減させ、がん患者とがんサバイバーの生活を向上させるという新たな目標を設定しました。このイニシアチブは、連邦政府のリソースを結集してがん研究を加速させ、予防法の改善を促進するものです。したがって、政府主導のがん対策への取り組みは、オンコロジーバイオシミラー市場を刺激します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界オンコロジーバイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のオンコロジーバイオシミラー市場：成長率分析
• 世界のオンコロジーバイオシミラー市場の実績：規模と成長, 2019-2024
• 世界のオンコロジーバイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界オンコロジーバイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のオンコロジーバイオシミラー市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 免疫調節薬
• 造血剤
• 顆粒球コロニー刺激因子（G-CSF）
• 世界のオンコロジーバイオシミラー市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 大腸がん
• 血液がん
• 好中球減少症がん
• 非小細胞肺がん
• その他のがんの種類
• 世界のオンコロジーバイオシミラー市場配信タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のオンコロジーバイオシミラー市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リツキシマブバイオシミラー
• トラスツズマブバイオシミラー
• ベバシズマブバイオシミラー
• ペムブロリズマブバイオシミラー
• 世界のオンコロジーバイオシミラー市場免疫調節剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サリドマイドバイオシミラー
• レナリドミドバイオシミラー
• ポマリドミドバイオシミラー
• 世界のオンコロジーバイオシミラー市場造血因子のサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポエチンバイオシミラー
• ダルベポエチンバイオシミラー
• 世界のオンコロジーバイオシミラー市場顆粒球コロニー刺激因子（G-CSF）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィルグラスチムバイオシミラー
• ペグフィルグラスチムバイオシミラー

第7章 地域別・国別分析

• 世界のオンコロジーバイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のオンコロジーバイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オンコロジーバイオシミラー市場：競合情勢
• オンコロジーバイオシミラー市場：企業プロファイル
  • Biocon Biologics Limited Overview, Products and Services, Strategy and Financial Analysis
  • Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • STADA Arzneimittel AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pfizer Inc.
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• BIOCAD
• Amgen Inc.
• F. Hoffmann-La Roche
• Baxter International Inc.
• Sanofi SA
• Mylan
• Samsung Bioepis
• Biogen International GmbH
• Merck & Co. Inc.
• Coherus Biosciences
• Eli Lilly and Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• オンコロジーバイオシミラー市場2029：新たな機会を提供する国
• オンコロジーバイオシミラー市場2029：新たな機会を提供するセグメント
• オンコロジーバイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oncology biosimilars are medications designed to closely resemble biologic cancer treatments, providing comparable physiological effects. A common side effect of cancer therapy is decreased white blood cell counts, which can elevate the risk of infections.

Within oncology biosimilars, key drug types include monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators primarily target pathways involved in treating multiple myeloma and several other cancers. These treatments are utilized for various cancer types such as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer. They are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2024 to $8.85 billion in 2025 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars.

The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $16.48 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence.

The expiration of patents on biologics utilized in cancer treatment is spurring the development of new oncology biosimilars. Biologics, derived from living organisms, have a limited patent lifespan, creating opportunities for the emergence of biosimilars similar but not identical alternatives to biologics that offer comparable effectiveness at reduced costs. Nearly 20 patents for oncology biologics are set to expire by 2023, prompting the production of new oncology biosimilars. This increased patent expiration rate is anticipated to drive demand for these biosimilars, fueling growth in the oncology biosimilars market.

Government initiatives aimed at combating cancer are poised to propel growth in the oncology biosimilars market. These initiatives denote actions or policies introduced by government bodies at various levels to address specific issues or achieve particular objectives. Efforts to reduce cancer rates create an environment conducive to the development and adoption of oncology biosimilars. For instance, in 2022, President Biden announced the revitalization of the Cancer Moonshot, setting new goals to halve the cancer death rate within 25 years and enhance the lives of cancer patients and survivors. This initiative marshals federal resources to accelerate cancer research, fostering improved prevention methods. Hence, government-led endeavors to combat cancer stimulate the oncology biosimilars market.

Pharmaceutical companies are increasingly allocating resources to research and development for the production of new oncology biosimilars. These companies are capitalizing on the growth potential of the expanding biosimilar market by enhancing their R&D processes to support the research and production of innovative biosimilars. For example, in May 2022, Biocon Biologics, a biopharmaceutical company based in India, and Viatris Inc., a US-based manufacturer of biosimilars, launched Abevmy (bevacizumab) in Canada, marking their third oncology biosimilar. Abevmy is a biosimilar of Roche's Avastin (bevacizumab), a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). By inhibiting VEGF, Abevmy plays a crucial role in preventing the formation of new blood vessels that tumors require for growth.

Major players in the oncology biosimilars sector are directing investments toward cancer drugs to combat the disease. Their investments serve as a critical link between top-tier cancer care and sustainable healthcare solutions. For example, in March 2023, Pfizer, in a merger with Seagen, invested $43 billion to combat cancer. This move enhances Pfizer's presence in the oncology field, contributing significantly to the fight against cancer, a primary global cause of mortality.

Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

North America was the largest region in the global oncology biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF)
• 2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Other Cancer Types
• 3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Monoclonal Antibody: Rituximab Biosimilars; Trastuzumab Biosimilars; Bevacizumab Biosimilars; Pembrolizumab Biosimilars
• 2) By Immunomodulators: Thalidomide Biosimilars; Lenalidomide Biosimilars; Pomalidomide Biosimilars
• 3) By Hematopoietic Agents: Epoetin Biosimilars; Darbepoetin Biosimilars
• 4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars; Pegfilgrastim Biosimilars
• Companies Mentioned: Biocon Biologics Limited; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Trends And Strategies

4. Oncology Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oncology Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncology Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncology Biosimilars Market Growth Rate Analysis
• 5.4. Global Oncology Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncology Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncology Biosimilars Total Addressable Market (TAM)

6. Oncology Biosimilars Market Segmentation

• 6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody
• Immunomodulators
• Hematopoietic Agents
• Granulocyte Colony-Stimulating Factor (G-CSF)
• 6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Colorectal Cancer
• Blood Cancer
• Neutropenia Cancer
• Non-Small Cell Lung Cancer
• Other Cancer Types
• 6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituximab Biosimilars
• Trastuzumab Biosimilars
• Bevacizumab Biosimilars
• Pembrolizumab Biosimilars
• 6.5. Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thalidomide Biosimilars
• Lenalidomide Biosimilars
• Pomalidomide Biosimilars
• 6.6. Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoetin Biosimilars
• Darbepoetin Biosimilars
• 6.7. Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Filgrastim Biosimilars
• Pegfilgrastim Biosimilars

7. Oncology Biosimilars Market Regional And Country Analysis

• 7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Biosimilars Market

• 8.1. Asia-Pacific Oncology Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Biosimilars Market

• 9.1. China Oncology Biosimilars Market Overview
• 9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Biosimilars Market

• 10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Biosimilars Market

• 11.1. Japan Oncology Biosimilars Market Overview
• 11.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Biosimilars Market

• 12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Biosimilars Market

• 13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Biosimilars Market

• 14.1. South Korea Oncology Biosimilars Market Overview
• 14.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Biosimilars Market

• 15.1. Western Europe Oncology Biosimilars Market Overview
• 15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Biosimilars Market

• 16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Biosimilars Market

• 17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Biosimilars Market

• 18.1. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Biosimilars Market

• 19.1. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Biosimilars Market

• 20.1. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Biosimilars Market

• 21.1. Eastern Europe Oncology Biosimilars Market Overview
• 21.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Biosimilars Market

• 22.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Biosimilars Market

• 23.1. North America Oncology Biosimilars Market Overview
• 23.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Biosimilars Market

• 24.1. USA Oncology Biosimilars Market Overview
• 24.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Biosimilars Market

• 25.1. Canada Oncology Biosimilars Market Overview
• 25.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Biosimilars Market

• 26.1. South America Oncology Biosimilars Market Overview
• 26.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Biosimilars Market

• 27.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Biosimilars Market

• 28.1. Middle East Oncology Biosimilars Market Overview
• 28.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Biosimilars Market

• 29.1. Africa Oncology Biosimilars Market Overview
• 29.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Oncology Biosimilars Market Competitive Landscape
• 30.2. Oncology Biosimilars Market Company Profiles
  • 30.2.1. Biocon Biologics Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. STADA Arzneimittel AG Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Biosimilars Market Other Major And Innovative Companies

• 31.1. Pfizer Inc.
• 31.2. Apotex Inc.
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Sandoz International GmbH
• 31.5. BIOCAD
• 31.6. Amgen Inc.
• 31.7. F. Hoffmann-La Roche
• 31.8. Baxter International Inc.
• 31.9. Sanofi SA
• 31.10. Mylan
• 31.11. Samsung Bioepis
• 31.12. Biogen International GmbH
• 31.13. Merck & Co. Inc.
• 31.14. Coherus Biosciences
• 31.15. Eli Lilly and Company

32. Global Oncology Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Biosimilars Market

34. Recent Developments In The Oncology Biosimilars Market

35. Oncology Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Oncology Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncology Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncology Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer